ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3214

Implementation of Treat to Target in Rheumatoid Arthritis through a Learning Collaborative

Daniel H. Solomon1, Bing Lu2, Elena Losina3, Jen Agosti4, Agnes Zak5, Cassandra Corrigan5, Zhi Yu6, Sara Lee5, Asaf Bitton7, LR Harrold8, Theodore Pincus9, Helga Radner10, Josef Smolen11, Liana Fraenkel12 and Jeffrey N. Katz13, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Brigham & Women's Hospital and Harvard Medical School, Boston, MA, 3Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopaedic Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 4JRA Consulting, Andover, MA, 5Brigham and Women's Hospital, Boston, MA, 6Rheumatology Immunology & Allergy, Brigham and Women's Hospital, Boston, MA, 7Medicine, Brigham and Women's Hospital, Boston, MA, 8University of Massachusetts Medical School, Worcester, MA, 9Rheumatology, Rush University Medical Center, Chicago, IL, 10Rheumatology, Medical University of Vienna, Vienna, Austria, 11Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 12Yale University School of Medicine, New Haven, CT, 13Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: practice improvement, quality improvement, randomized trials and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, November 16, 2016

Title: Rheumatoid Arthritis – Clinical Aspects VII: The Impact of Treating to Target

Session Type: ACR Concurrent Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: Treat to target (TTT) is a recommended strategy in the management of rheumatoid arthritis (RA), but various studies suggest that its uptake in routine US care is sub-optimal.  We carried out a randomized controlled trial of a Learning Collaborative to facilitate implementation of TTT.

Methods: We recruited 11 rheumatology sites from the US and randomized them into 2 groups: 5 sites received the Learning Collaborative intervention over 9 months and the other 6 sites formed a wait-list control group.  The Learning Collaborative used a description of the problem with strategies for improvement (Model for Improvement with Change Package) and action phases.  The intervention included: 1 face to face meeting and 8 learning sessions via webinar; use of a web-based tool for sharing results of plan-do-study-act cycles; and collection by sites of their monthly improvement measures assessing progress.  The primary outcome was the between group difference in the change in TTT implementation, as measured in medical records by study staff at baseline and follow-up.  TTT implementation was scored using 4 items: shared-decision making, choice of a target, use of a disease activity measure (DAM), and changing treatments based on the target and DAM.  The TTT implementation was scored on a 0-100% scale based on the presence/absence of the 4 items. The between group difference was measured at the patient-level, accounting for the clustering in a linear mixed model. 

Results: 23 providers participated at the five intervention sites and 23 at the six control sites.  The chart review included 320 RA patients from intervention and 321 from control.  The patient groups were well matched, with a mean age of 60 years, 78% were female, 64% were seropositive, and treatments were similar at the start of follow-up.  At baseline, mean TTT implementation score was 11% in both groups (p = 0.93) (see Figure). At follow-up, TTT implementation score in the intervention arm was 46% (SD 36%) compared with 14% (SD 28%) in the control arm (p < 0.0001) (see Figure).  Improvements were observed for all four items in the implementation score (see Table).  No negative consequences from the intervention were observed, with similar use of laboratory testing and x-rays, as well as similar rates of adverse events in the intervention and control arms.

Conclusion: A Learning Collaborative was an effective intervention to improve implementation of TTT for RA.  Future steps will focus on analyzing the sustainability of change.


Disclosure: D. H. Solomon, None; B. Lu, None; E. Losina, None; J. Agosti, None; A. Zak, None; C. Corrigan, None; Z. Yu, None; S. Lee, None; A. Bitton, None; L. Harrold, Corrona, LLC, 1,Pfizer Inc, 2; T. Pincus, Health Report Services Inc., 4; H. Radner, Amgen, 9; J. Smolen, Abbvie, BMS, MSD, Pfizer, Roche, 2,Abbvie, Astra-Zeneca, BMS, Boehringer-Ingelheim, Celgene, Celtrion, GSK, ILTOO, Janssen, Lilly, MSD, Novartis-Sandoz, Pfizer, Roche-Chugai, Samsung, UCB, 5; L. Fraenkel, None; J. N. Katz, None.

To cite this abstract in AMA style:

Solomon DH, Lu B, Losina E, Agosti J, Zak A, Corrigan C, Yu Z, Lee S, Bitton A, Harrold L, Pincus T, Radner H, Smolen J, Fraenkel L, Katz JN. Implementation of Treat to Target in Rheumatoid Arthritis through a Learning Collaborative [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/implementation-of-treat-to-target-in-rheumatoid-arthritis-through-a-learning-collaborative/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/implementation-of-treat-to-target-in-rheumatoid-arthritis-through-a-learning-collaborative/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology